DexCom (DXCM)
(Delayed Data from NSDQ)
$69.00 USD
-0.70 (-1.00%)
Updated Nov 5, 2024 04:00 PM ET
After-Market: $68.91 -0.09 (-0.13%) 7:56 PM ET
3-Hold of 5 3
C Value C Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$69.00 USD
-0.70 (-1.00%)
Updated Nov 5, 2024 04:00 PM ET
After-Market: $68.91 -0.09 (-0.13%) 7:56 PM ET
3-Hold of 5 3
C Value C Growth A Momentum B VGM
Zacks News
DexCom (DXCM) Stock Rallies on Apple Watch Partnership
by Ryan McQueeney
Shares of DexCom (DXCM) popped nearly 5% in afternoon trading Monday after Apple (AAPL) announced that it has partnered with the company to deliver glucose monitoring on its latest Apple Watch operating system.
DexCom (DXCM) Down 9.6% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
DexCom (DXCM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
DexCom (DXCM) Q1 Loss Narrower than Expected, Revenues Miss
by Zacks Equity Research
DexCom Inc. (DXCM) reported a loss of 49 cents per share in the first quarter of 2017, narrower than the Zacks Consensus Estimate of a loss of 55 cents.
Medical Product Q1 Earnings Due on May 2: BDX, DXCM & More
by Zacks Equity Research
The medical product sector shines bright at the moment owing to the prevalence of minimally invasive surgeries, liquid biopsy tests, and use of IT for ensuring quick and improved patient care among other things.
DexCom (DXCM) Up 4.6% Since Earnings Report: Can It Continue?
by Zacks Equity Research
DexCom (DXCM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
DexCom Gains as CMS Announces Criteria for G5 Mobile CGM
by Zacks Equity Research
The Centers for Medicare & Medicaid Services published an article clarifying the criteria for coverage of its DexCom (DXCM) G5 Mobile CGM system for patients with diabetes and on intensive insulin therapy.
DexCom (DXCM) Incurs Narrower Loss in Q4, Beats on Revenues
by Zacks Equity Research
DexCom Inc. (DXCM) reported loss of nine cents per share in the fourth quarter of 2016, narrower than the Zacks Consensus Estimate of a loss of 10 cents.
Should You Buy DexCom (DXCM) Ahead of Earnings?
by Zacks Equity Research
DexCom (DXCM) looks like an exciting pick for investors as it is poised to beat at earnings season.
DexCom (DXCM) Q4 Earnings: What to Expect from the Stock?
by Zacks Equity Research
DexCom, Inc. (DXCM) is set to report fiscal fourth-quarter 2017 results on Feb 28.
DexCom Looking Forward to Strong Revenues in Q4 and 2016
by Zacks Equity Research
DexCom, Inc. (DXCM), a renowned medical device company, reported that it expects preliminary, unaudited revenue of approximately $168 million for the fourth quarter ended Dec 31, 2016.
DexCom (DXCM) Gains FDA Approval for G5 Mobile CGM System
by Zacks Equity Research
San Diego, CA-based DexCom, Inc. (DXCM), a renowned medical device company, announced the U.S. FDA approval for its G5 Mobile CGM (continuous glucose monitoring) system.
3 Med-Instrument Stocks Poised to Gain this Earnings Season
by Zacks Equity Research
2015 is forecasted to be a transition year for the medical instruments sector.